CoChat

Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants

Open access

The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index; 31 of the 46 sources its claims cite were checked for support.

Abstract

Metal-dependent histone deacetylases (HDACs) are key epigenetic regulators that represent promising therapeutic targets for the treatment of numerous human diseases. Yet the currently FDA-approved HDAC inhibitors nonspecifically target at least several of the 11 structurally similar but functionally different HDAC isozymes, which hampers their broad usage in clinical settings. Selective inhibitors targeting single HDAC isozymes are being developed, but precise understanding in molecular terms of their selectivity remains sparse. Here, we show that HDAC8-selective inhibitors adopt a L-shaped conformation required for their binding to a HDAC8-specific pocket formed by HDAC8 catalytic tyrosine and HDAC8 L1 and L6 loops. In other HDAC isozymes, a L1-L6 lock sterically prevents L-shaped inhibitor binding. Shielding of the HDAC8-specific pocket by protein engineering decreases potency of HDAC8-selective inhibitors and affects catalytic activity. Collectively, our results unravel key HDAC8 active site structural and functional determinants important for the design of next-generation chemical probes and epigenetic drugs.

Overview

CoChat Summary

## TL;DR

This paper shows that HDAC8-selective inhibitors bind a specific HDAC8 pocket shaped by the catalytic tyrosine and the L1/L6 loops, and that an L-shaped inhibitor conformation is required for this selectivity. The authors combine crystal structures, mutagenesis, biophysical assays, docking, MD, and schistosome assays to show that small changes in inhibitor structure or loop conformation strongly affect potency and selectivity.

## Key findings

  • PCI-34051, NCC-149, and Quisinostat (QSN) inhibited hHDAC8 and smHDAC8 in the submicromolar range; the reported IC50 values were 77.7 ± 18.1 nM, 44 ± 4.9 nM, and 64.4 ± 3.4 nM for hHDAC8, and 435.8 ± 61 nM, 95.4 ± 9.3 nM, and 303.4 ± 39 nM for smHDAC8, respectively.
  • The crystal structures showed that the HDAC8-selective inhibitors PCI-34051 and NCC-149 adopt an L-shaped conformation and contact the catalytic tyrosine and L6 loop, whereas QSN binds in a more canonical mode.
  • HDAC8-selective inhibition was attributed to a specific “HDAC8-selective pocket” formed by the catalytic tyrosine plus L1 and L6 loop residues; in other HDAC isozymes, a L1-L6 lock sterically blocks this pocket.
  • Mutating the L1/L6 region reduced activity and weakened inhibition: all mutants had about a 5°C lower Tm than wild type, hHDAC8 mutants showed around 10-fold activity loss in point mutants/L6 replacements, and the triple mutant showed almost no activity; PCI-34051 IC50 increased by more than 64-fold for the triple mutant.

## Methods

  • Combined structural, biochemical, and functional analysis of hHDAC8 and smHDAC8, including X-ray crystallography of inhibitor-bound HDAC8 complexes, mutational analysis of L1/L6 loop variants, activity/inhibition assays, ITC, DSF, docking, MD simulations, and parasite culture assays.
  • Used recombinant WT and mutant hHDAC8 and smHDAC8 proteins expressed in bacteria; apo smHDAC8 crystals were soaked with inhibitors, and one hHDAC8-mL6/QSN complex structure was obtained by co-crystallization.
  • Tested inhibitor effects on S. mansoni schistosomula and adult worms using microscopy-based viability and egg-production assays; schistosomula were treated at 25, 50, and 100 µM, and TUNEL was used to detect DNA strand breaks after 100 µM treatment.

## Limitations

  • The authors state that they were not able to obtain well-diffracting crystals of hHDAC8 complexed with PCI-34051, NCC-149, and QSN; only the hHDAC8-mL6/QSN complex yielded exploitable structural data.
  • They note that several structures, including QSN bound to hHDAC8-mL6, are influenced by crystal packing, making it difficult to know whether the observed conformations are biologically favored in solution.
  • Evident from the text: the mutational analysis was limited by solubility, because all smHDAC8 mutants except point mutants were insoluble, which restricted structural/biophysical follow-up.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.8b01087

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

14 Valid · 0 Not valid · 6 Not checked · 157 Own results and interpretations

95 more claims

Create a free account to see all 177 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 62
  • Probably not a substantial claim. 17

Create a free account to see these claims.

Citations

Cites

Show all 84 references

Cited by

See all 122

Metadata

Authors
Marek, M., Shaik, T. B., Heimburg, T., Chakrabarti, A., Lancelot, J., Ramos-Morales, E., Da Veiga, C., Kalinin, D., Melesina, J., Robaa, D., Schmidtkunz, K., Suzuki, T., Holl, R., Ennifar, E., Pierce, R. J., Jung, M., Sippl, W., & Romier, C.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Martin Luther University Halle-Wittenberg (DE)
  • University of Freiburg (DE)
  • Institut de Génétique et Biologie Moléculaire et Cellulaire (IGBMC), Département de Biologie Structurale Intégrative, Université de Strasbourg, Centre National de la Recherche Scientifique (CNRS UMR7104), Institut National de la Santé et de la Recherche Médicale (INSERM U1258), 1 rue Laurent Fries, 67404 Illkirch Cedex, France
  • University of Münster (DE)
  • Kyoto Prefectural University of Medicine (JP)
  • Universität Hamburg (DE)
Corresponding author
  • Marek, Martin
  • Romier, Christophe
Venue
Journal of Medicinal Chemistry
Published
2018-10-22
Volume
61
Issue
22
Pages
10000-10016
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2897192913
Cited by
122
References
80
Citations by year
2026: 13 · 2025: 14 · 2024: 16 · 2023: 14 · 2022: 19 · 2021: 16 · 2020: 18 · 2019: 10 · 2018: 1
FWCI
3.75
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Journal of Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • DORA PSI (Paul Scherrer Institute) (submittedVersion)
Funders
  • Agence Nationale de la Recherche (ANR-10-LABX-0030-INRT, ANR-10-IDEX-0002-02)
  • Deutsche Forschungsgemeinschaft (Si868/13-1, Ju295/13-1)
  • Seventh Framework Programme (241865, 602080)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords
HDAC8, catalytic tyrosine, protein engineering, epigenetic drug design, chemical probes, epigenetic regulators
MeSH terms
Amino Acid Sequence, Histone Deacetylases, Humans, Hydroxamic Acids, Indoles, Repressor Proteins, Structure-Activity Relationship, Substrate Specificity, Triazoles, Catalytic Domain, Molecular Dynamics Simulation, Histone Deacetylase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants. https://app.cochat.ai/papers/10.1021/acs.jmedchem.8b01087
The paper
Marek, M., Shaik, T. B., Heimburg, T., Chakrabarti, A., Lancelot, J., Ramos-Morales, E., Da Veiga, C., Kalinin, D., Melesina, J., Robaa, D., Schmidtkunz, K., Suzuki, T., Holl, R., Ennifar, E., Pierce, R. J., Jung, M., Sippl, W., & Romier, C. (2018). Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.8b01087

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.